ArticleFrontiers in medicine2025
Prevalence of vision impairment in Rwanda: a hospital-based study.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vision impairment (VI) is a global health challenge with its impact cutting across ages, gender, and all domains of life. A shift in global demographics due to increasing life expectancy is expected to increase the burden of VI. Aim: This study sought to determine the prevalence of VI in the general population among selected public hospitals in Kigali and southern Rwanda. Methods: This retrospective hospital-based study used five public hospitals from Kigali and Southern Rwanda. Patient files from 1st January 2018 to 31st December 2023 were sampled, and files with VI according to defined criteria were selected, and data were collected. Data were analyzed using descriptive and inferential statistics. Results: Most patients who presented to the hospitals were female (60.7%). The prevalence of VI ranged between 8.1 and 18.2%. VI was more prevalent in females than in males (18.0% vs. 13.7%). Additionally, VI was most prevalent among the elderly (29.1%). The leading causes of VI were diseases of the lens and normal globe diseases. The risk of VI was significantly higher in males (AOR: 1.25; 95% CI: 1.16-1.34), the elderly (AOR: 1.57; 95% CI: 1.40-1.76), and those with diseases of the lens (AOR: 2.17; 95% CI: 1.88-2.51). Conclusion: The burden of VI in Rwanda is expected to increase due to a growing youthful population. Sustained efforts, including improving human resources and addressing the unmet demands of cataract and refractive error, are critical to avert the impending public health challenge.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.